Long-acting muscarinic antagonist - Mylan/Pfizer

Drug Profile

Long-acting muscarinic antagonist - Mylan/Pfizer

Latest Information Update: 20 Dec 2013

Price : $50

At a glance

  • Originator Pfizer
  • Developer Mylan
  • Class Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Respiratory tract disorders

Most Recent Events

  • 18 Dec 2013 Clinical trials in Respiratory tract disorders in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top